ロード中...
Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis
OBJECTIVE: Cerebrospinal fluid (CSF) biomarkers are shown to facilitate a risk identification of patients with mild cognitive impairment (MCI) into different risk levels of progression to Alzheimer’s disease (AD). Knowing a patient’s risk level provides an opportunity for earlier interventions, whic...
保存先:
| 出版年: | Pharmacoecon Open |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6103924/ https://ncbi.nlm.nih.gov/pubmed/29623628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-017-0054-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|